Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time ...

End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response rate of 61% compared to 40% for investigator’s choice of chemotherapy. Pfizer ...